NSABP Patient Registry and Biospecimen Profiling Repository
18 Years
N/A
Both
Colorectal Cancer
Trial Information
NSABP Patient Registry and Biospecimen Profiling Repository
Tissue blocks from the primary tumor site and an uninvolved margin of resection (normal
tissue) from consenting patients will be submitted and stored at the NSABP Division of
Pathology, in the NSABP Biospecimen Profiling Repository. Tissue specimens will be used to
profile molecular characteristics, including actionable mutations most commonly identified
in colorectal cancer. Specimens may be further interrogated by other methods to discover
additional mechanisms and targetable genetic alterations that may predict sensitivity or
resistance to drug therapies.
The repository will be populated, maintained, and analyzed through continuous patient
recruitment. Patient tumor specimens will be interrogated to characterize an individual's
molecular profile. At a future date for discovery purposes, the normal tissue may be
profiled for comparison with the profile of the tumor tissue. NSABP will hold a database
with molecular profiles and relevant patient information. As agents become available for
clinical study, particularly those matching specified profiles, the treating physician will
be contacted so that the patient may be offered participation in that trial via a separate
consent process. Each NSABP trial will have a defined molecular profile for entry which
will be specific to the agent(s) under study. The MPR-1 patient registry and tissue
repository and all treatment protocols associated with MPR-1 are being developed as part of
the NSABP Oncology-Genome Assessment Guided Medicine (N-GAMe) Program.
This registry and repository platform uses a translational science approach for more
personalized therapy for patients with mCRC. This analysis provides an individual molecular
profile in an attempt to direct each patient's treatment based on the pattern of genetic
alterations. These efforts also may aid in the discovery of with or without new gene
targets for future drug development.
Approximately 1000-2000 tumor (with or without) normal tissue specimens from living mCRC
patients will be collected, stored, and analyzed as part of this biospecimen repository. It
is anticipated that 200-400 participants will be registered within the first year.
Inclusion Criteria:
- The patient must have a diagnosis of metastatic colorectal cancer.
- Representative formalin-fixed paraffin-embedded (FFPE) tissue blocks from the primary
colorectal tumor with corresponding pathology report must be available for release by
the local pathology department. If available for release, a separate FFPE tissue
block from an uninvolved margin of resection (normal tissue) is also requested.
- The patient must have a life-expectancy of greater than or equal to 6 months.
Exclusion Criteria:
- History of non-CRC malignancy unless the patient is considered by the physician to be
disease-free and at low risk for recurrence.
- Known comorbid medical conditions that would preclude investigational treatment
(e.g., active hepatitis B or C; symptomatic cardiac disease; renal insufficiency;
bone marrow impairment).
- Psychiatric or addictive disorders or other conditions that, in the opinion of the
investigator, would preclude investigational treatment.
Type of Study:
Observational [Patient Registry]
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
To characterize common genetic/molecular profiles associated with colorectal cancer (CRC)
Outcome Description:
This is a living registry with no end date provided continued funding.
Outcome Time Frame:
From start of study through study completion at approximately 6 months
Safety Issue:
No
Principal Investigator
Norman Wolmark, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
NSABP Foundation, Inc.
Authority:
United States: Institutional Review Board
Study ID:
NSABP MPR-1
NCT ID:
NCT01793805
Start Date:
February 2013
Completion Date:
June 2013
Related Keywords:
- Colorectal Cancer
- Colorectal Neoplasms
Name | Location |
|---|---|
| MD Anderson Cancer Center Orlando | Orlando, Florida 32806 |
| St. Luke's Mountain States Tumor Institute - Boise | Boise, Idaho 83712-6297 |
| University of Florida | Gainesville, Florida 32610-0277 |
| Thomas Jefferson University Hospital | Philadelphia, Pennsylvania 19131 |
